特拉华州威尔明顿，2025 年 12 月 30 日（环球新闻通讯）-- Aimfinity Investment Corp. I（OTC: AIMTF）（“公司”），一家注册为开曼群岛豁免公司的空白支票公司，今天宣布，为了将公司必须完成初始商业合并的日期从 2025 年 12 月 28 日延长至 2026 年 1 月 28 日，I-Fa Chang（公司的赞助商经理）于 2025 年 12 月 28 日已向其信托账户（“信托账户”）存入总计 500 美元（“月度延长付款”）。
根据公司当前章程（“当前章程”）的修订和重述的备忘录及章程，自 2025 年 10 月 28 日至 2026 年 7 月 28 日，或董事会可能决定的更早日期，公司可以通过每月向信托账户存入月度延长付款来按月延长。这是根据公司当前章程寻求的九次月度延长中的第三次。
关于 Aimfinity Investment Corp. I
Aimfinity Investment Corp. I 是一家特殊目的收购公司（SPAC），专注于与高增长潜力的企业合并，并促进其进入资本市场。
附加信息及获取途径
如之前披露的，2023 年 10 月 13 日，AIMA 与 Docter、Aimfinity Investment Merger Sub I（开曼群岛豁免公司，AIMA 的全资子公司，以下简称 “买方”）及 Aimfinity Investment Merger Sub II, Inc.（特拉华州公司，买方的全资子公司，以下简称 “合并子公司”）签署了某项合并协议（可能会不时修订、补充或以其他方式修改，以下简称 “合并协议”），根据该协议，AIMA 拟与 Docter 进行商业合并，涉及重新注册合并和收购合并。此新闻稿并未包含所有应考虑的关于拟议商业合并的信息，也不打算作为任何投资决策或其他与商业合并相关的决策的基础。建议 AIMA 的股东和其他相关人士在可用时阅读代理声明/招股说明书及其修订和与拟议商业合并相关的其他文件，因为这些材料将包含关于 AIMA、买方或 Docter 及拟议商业合并的重要信息。拟议商业合并的代理声明/招股说明书及其他相关材料已邮寄给截至 2025 年 2 月 25 日的 AIMA 股东，以便对拟议商业合并进行投票。这些股东在可用时也可以在美国证券交易委员会（SEC）的网站 www.sec.gov 上免费获取代理声明/招股说明书及其他提交给 SEC 的文件，或向 AIMA 位于特拉华州威尔明顿市第 9 街 221 号 PMB 235 的主要办公室提出请求。
前瞻性声明
本新闻稿包含某些根据 1933 年证券法（修订版）（“证券法”）和 1934 年证券交易法（修订版）所定义的 “前瞻性声明”。这些声明不是历史事实，包括关于此处描述的拟议交易及各方的观点和预期的声明，均为前瞻性声明。这些声明包括但不限于关于拟议交易的声明，包括预期的初始企业价值和交易后股权价值、拟议交易的好处、整合计划、预期的协同效应和收入机会、预期的未来财务和运营表现及结果，包括增长的估计、合并公司的预期管理和治理，以及拟议交易的预期时间。这些前瞻性声明中的 “期望”、“相信”、“估计”、“打算”、“计划” 等类似表达表明前瞻性声明。这些前瞻性声明并不保证未来的表现，并且受到各种风险和不确定性、假设（包括关于一般经济、市场、行业和运营因素的假设），无论是已知的还是未知的，这可能导致实际结果与所指示或预期的结果有重大差异。
这些风险和不确定性包括但不限于：(i) 与预期的业务合并完成时间和可能性相关的风险，包括由于一个或多个交易完成条件未得到满足或被放弃而导致交易可能无法完成的风险，例如监管批准未能及时获得或以其他方式获得，或政府实体禁止、延迟或拒绝批准交易的完成，或要求与此类批准相关的某些条件、限制或限制；(ii) 与 AIMA 和 Docter 成功整合业务的能力相关的风险；(iii) 可能导致适用交易协议终止的任何事件、变化或其他情况的发生；(iv) AIMA 或 Docter 的财务状况、业绩、运营或前景可能发生重大不利变化的风险；(v) 由于拟议交易而导致管理时间被持续业务运营干扰的风险；(vi) 与拟议交易相关的任何公告可能对 AIMA 证券的市场价格产生不利影响的风险；(vii) 拟议交易及其公告可能对 Docter 保留客户、留住和招聘关键人员以及维持与供应商和客户的关系及其经营业绩和业务整体产生不利影响的风险；(viii) 与医疗器械行业相关的风险，包括但不限于政府监管和执法变化、市场竞争、竞争产品和定价活动；以及 (ix) 与合并公司增强其产品和服务、执行其商业战略、扩大客户基础和维持与商业伙伴的稳定关系的能力相关的风险。
有关风险和不确定性的进一步列表和描述可以在 2022 年 4 月 26 日向证券交易委员会（“SEC”）提交的与 AIMA 首次公开募股相关的招股说明书中找到（文件编号：333-263874），在 2024 财年截至 2025 年 4 月 15 日向 SEC 提交的 AIMA 年度报告（10-K 表格），以及在 2025 年 3 月 6 日向 SEC 提交的与拟议交易相关的最终招股说明书/代理声明中（文件编号：333-284658）（“最终招股说明书”），以及其他各方可能向 SEC 提交或提供的文件，建议您阅读。如果这些风险或不确定性中的一个或多个变为现实，或者基本假设被证明不正确，实际结果可能与这些前瞻性声明所指示或预期的结果有重大差异。因此，您被警告不要对这些前瞻性声明过于依赖。前瞻性声明仅与其作出之日相关，AIMA、Docter 及其子公司或附属公司没有义务更新前瞻性声明，以反映作出之日后的事件或情况，除非法律或适用法规要求。
附加信息及获取途径
与此处描述的拟议交易相关，购买方于 2025 年 3 月 6 日向 SEC 提交了最终招股说明书。代理声明和代理卡已邮寄给截至 2025 年 2 月 25 日的 AIMA 股东。AIMA 的股东还可以免费从 AIMA 获取最终招股说明书。最终招股说明书也可以在 SEC 网站 www.sec.gov 上免费获取。AIMA 的投资者和证券持有人被敦促阅读这些材料（包括任何修订或补充）以及 AIMA 在拟议交易中提交给 SEC 的任何其他相关文件，因为这些文件将包含有关 AIMA、Docter 和拟议交易的重要信息。
征求参与者
根据 SEC 规则，AIMA、Docter 及其各自的董事、高级管理人员、其他管理层成员和员工可能被视为参与与此处描述的拟议交易相关的 AIMA 股东的代理征求。有关根据 SEC 规则可能被视为参与 AIMA 股东代理征求的人员的信息已在最终招股说明书中列出。
无报价或征求
本新闻稿不是代理声明或对任何证券的代理、同意或授权的征求，也不构成对 AIMA、购买方或 Docter 的任何证券的出售要约或购买要约的征求，也不应在任何州或司法管辖区内进行任何此类证券的出售，若在该州或司法管辖区内的证券法规定下，未注册或资格审查之前，此类要约、征求或出售将是非法的。证券的任何要约仅应通过符合《证券法》第 10 条要求的招股说明书或其豁免进行。
Aimfinity Investment Corp. I
I-Fa Chang
首席执行官
221 W 9th St, PMB 235
特拉华州威尔明顿 19801
ceo@aimfinityspac.com
<img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ETTFNQ00zTXpRd01UUTJJelV3TURFeE56Y3hOZz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ETTFNQ00zTXpRd01UUTJJelV3TURFeE56Y3hOZz09"/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTkxMzI3NzMtNjdmMy00ZDNlLWI4OTgtODM2MTgzYzlhYTU1LTUwMDExNzcxNi0yMDI1LTEyLTMwLWVu/tiny/Aimfinity-Investment-Corp-I.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTkxMzI3NzMtNjdmMy00ZDNlLWI4OTgtODM2MTgzYzlhYTU1LTUwMDExNzcxNi0yMDI1LTEyLTMwLWVu/tiny/Aimfinity-Investment-Corp-I.png"/>

AIMUF

Aimfinity Investment Corp. I 已将其初始商业合并的截止日期从 2025 年 12 月 28 日延长至 2026 年 1 月 28 日。这次延长是由于赞助商的经理 I-Fa Chang 向信托账户存入了 500 美元的押金。该公司可以每月延长截止日期，直到 2026 年 7 月 28 日。这是九次可能延长中的第三次。Aimfinity 专注于与高增长企业合并，并已与 Docter 签署了合并协议。建议股东查看代理声明/招股说明书，以获取有关拟议商业合并的重要细节

Wilmington, Delaware, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Aimfinity Investment Corp. I (OTC: AIMTF) (the “Company”), a blank check company incorporated as a Cayman Islands exempted company, today announced that, in order to extend the date by which the Company mush complete its initial business combination from December 28, 2025 to January 28, 2026, on December 28, 2025, I-Fa Chang, manager of the sponsor of the Company, has deposited into its trust account (the “Trust Account”) an aggregate of $500 (the “Monthly Extension Payment”).
<div class="lb-trans">特拉华州威尔明顿，2025 年 12 月 30 日（环球新闻通讯）-- Aimfinity Investment Corp. I（OTC: AIMTF）（“公司”），一家注册为开曼群岛豁免公司的空白支票公司，今天宣布，为了将公司必须完成初始商业合并的日期从 2025 年 12 月 28 日延长至 2026 年 1 月 28 日，I-Fa Chang（公司的赞助商经理）于 2025 年 12 月 28 日已向其信托账户（“信托账户”）存入总计 500 美元（“月度延长付款”）。
</div>Pursuant to the Company’s amended &amp; restated memorandum and articles of association effective at this time (the “Current Charter”), the Company may extend on a monthly basis from October 28, 2025 until July 28, 2026 or such an earlier date as may be determined by its board to complete a business combination by depositing the Monthly Extension Payment for each month into the Trust Account. This is the third of nine monthly extensions sought under the Current Charter of the Company.
<div class="lb-trans">根据公司当前章程（“当前章程”）的修订和重述的备忘录及章程，自 2025 年 10 月 28 日至 2026 年 7 月 28 日，或董事会可能决定的更早日期，公司可以通过每月向信托账户存入月度延长付款来按月延长。这是根据公司当前章程寻求的九次月度延长中的第三次。
</div>About Aimfinity Investment Corp. I
<div class="lb-trans">关于 Aimfinity Investment Corp. I
</div>Aimfinity Investment Corp. I is a special purpose acquisition company (SPAC) focused on merging with high-growth potential businesses and facilitating their entry into the capital markets.
<div class="lb-trans">Aimfinity Investment Corp. I 是一家特殊目的收购公司（SPAC），专注于与高增长潜力的企业合并，并促进其进入资本市场。
</div>Additional Information and Where to Find It
<div class="lb-trans">附加信息及获取途径
</div>As previously disclosed, on October 13, 2023, AIMA entered into that certain Agreement and Plan of Merger (as may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and between AIMA, Docter, Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and wholly-owned subsidiary of AIMA (“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of Purchaser (“Merger Sub”), pursuant to which AIMA is proposing to enter into a business combination with Docter involving an reincorporation merger and an acquisition merger. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. AIMA’s shareholders and other interested persons are advised to read, when available, the proxy statement/prospectus and the amendments thereto and other documents filed in connection with the proposed business combination, as these materials will contain important information about AIMA, Purchaser or Docter, and the proposed business combination. The proxy statement/prospectus and other relevant materials for the proposed business combination have been mailed to shareholders of AIMA as of the record date of February 25, 2025, established for voting on the proposed business combination. Such shareholders will also be able to obtain copies of the proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to AIMA’s principal office at 221 W 9th St, PMB 235 Wilmington, Delaware 19801.
<div class="lb-trans">如之前披露的，2023 年 10 月 13 日，AIMA 与 Docter、Aimfinity Investment Merger Sub I（开曼群岛豁免公司，AIMA 的全资子公司，以下简称 “买方”）及 Aimfinity Investment Merger Sub II, Inc.（特拉华州公司，买方的全资子公司，以下简称 “合并子公司”）签署了某项合并协议（可能会不时修订、补充或以其他方式修改，以下简称 “合并协议”），根据该协议，AIMA 拟与 Docter 进行商业合并，涉及重新注册合并和收购合并。此新闻稿并未包含所有应考虑的关于拟议商业合并的信息，也不打算作为任何投资决策或其他与商业合并相关的决策的基础。建议 AIMA 的股东和其他相关人士在可用时阅读代理声明/招股说明书及其修订和与拟议商业合并相关的其他文件，因为这些材料将包含关于 AIMA、买方或 Docter 及拟议商业合并的重要信息。拟议商业合并的代理声明/招股说明书及其他相关材料已邮寄给截至 2025 年 2 月 25 日的 AIMA 股东，以便对拟议商业合并进行投票。这些股东在可用时也可以在美国证券交易委员会（SEC）的网站 www.sec.gov 上免费获取代理声明/招股说明书及其他提交给 SEC 的文件，或向 AIMA 位于特拉华州威尔明顿市第 9 街 221 号 PMB 235 的主要办公室提出请求。
</div>Forward-Looking Statements
<div class="lb-trans">前瞻性声明
</div>This press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about the proposed transactions described herein, and the parties’ perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transaction, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the proposed transactions. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.
<div class="lb-trans">本新闻稿包含某些根据 1933 年证券法（修订版）（“证券法”）和 1934 年证券交易法（修订版）所定义的 “前瞻性声明”。这些声明不是历史事实，包括关于此处描述的拟议交易及各方的观点和预期的声明，均为前瞻性声明。这些声明包括但不限于关于拟议交易的声明，包括预期的初始企业价值和交易后股权价值、拟议交易的好处、整合计划、预期的协同效应和收入机会、预期的未来财务和运营表现及结果，包括增长的估计、合并公司的预期管理和治理，以及拟议交易的预期时间。这些前瞻性声明中的 “期望”、“相信”、“估计”、“打算”、“计划” 等类似表达表明前瞻性声明。这些前瞻性声明并不保证未来的表现，并且受到各种风险和不确定性、假设（包括关于一般经济、市场、行业和运营因素的假设），无论是已知的还是未知的，这可能导致实际结果与所指示或预期的结果有重大差异。
</div>Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the proposed business combination, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the businesses; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iv) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of AIMA or Docter; (v) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of AIMA’s securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Docter to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (viii) risks relating to the medical device industry, including but not limited to governmental regulatory and enforcement changes, market competitions, competitive product and pricing activity; and (ix) risks relating to the combined company’s ability to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationship with its business partners.
<div class="lb-trans">这些风险和不确定性包括但不限于：(i) 与预期的业务合并完成时间和可能性相关的风险，包括由于一个或多个交易完成条件未得到满足或被放弃而导致交易可能无法完成的风险，例如监管批准未能及时获得或以其他方式获得，或政府实体禁止、延迟或拒绝批准交易的完成，或要求与此类批准相关的某些条件、限制或限制；(ii) 与 AIMA 和 Docter 成功整合业务的能力相关的风险；(iii) 可能导致适用交易协议终止的任何事件、变化或其他情况的发生；(iv) AIMA 或 Docter 的财务状况、业绩、运营或前景可能发生重大不利变化的风险；(v) 由于拟议交易而导致管理时间被持续业务运营干扰的风险；(vi) 与拟议交易相关的任何公告可能对 AIMA 证券的市场价格产生不利影响的风险；(vii) 拟议交易及其公告可能对 Docter 保留客户、留住和招聘关键人员以及维持与供应商和客户的关系及其经营业绩和业务整体产生不利影响的风险；(viii) 与医疗器械行业相关的风险，包括但不限于政府监管和执法变化、市场竞争、竞争产品和定价活动；以及 (ix) 与合并公司增强其产品和服务、执行其商业战略、扩大客户基础和维持与商业伙伴的稳定关系的能力相关的风险。
</div>A further list and description of risks and uncertainties can be found in the prospectus filed with the Securities and Exchange Commission (the “SEC”) on April 26, 2022 relating to AIMA’s initial public offering (File No. 333-263874), the annual report of AIMA on Form 10-K for the fiscal year ended on December 31, 2024, filed with the SEC on April 15, 2025, and in the final prospectus/proxy statement filed with the SEC on March 6, 2025 relating to the proposed transactions (File No. 333-284658) (the “Final Prospectus”), and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and AIMA, Docter, and their subsidiaries or affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
<div class="lb-trans">有关风险和不确定性的进一步列表和描述可以在 2022 年 4 月 26 日向证券交易委员会（“SEC”）提交的与 AIMA 首次公开募股相关的招股说明书中找到（文件编号：333-263874），在 2024 财年截至 2025 年 4 月 15 日向 SEC 提交的 AIMA 年度报告（10-K 表格），以及在 2025 年 3 月 6 日向 SEC 提交的与拟议交易相关的最终招股说明书/代理声明中（文件编号：333-284658）（“最终招股说明书”），以及其他各方可能向 SEC 提交或提供的文件，建议您阅读。如果这些风险或不确定性中的一个或多个变为现实，或者基本假设被证明不正确，实际结果可能与这些前瞻性声明所指示或预期的结果有重大差异。因此，您被警告不要对这些前瞻性声明过于依赖。前瞻性声明仅与其作出之日相关，AIMA、Docter 及其子公司或附属公司没有义务更新前瞻性声明，以反映作出之日后的事件或情况，除非法律或适用法规要求。
</div>Additional Information and Where to Find It
<div class="lb-trans">附加信息及获取途径
</div>In connection with the proposed transactions described herein, Purchaser filed the Final Prospectus with the SEC on March 6, 2025. The proxy statement and a proxy card has been mailed to AIMA’s shareholders of record as of February 25, 2025. Shareholders of AIMA will also be able to obtain a copy of the Final Prospectus without charge from AIMA. The Final Prospectus may also be obtained without charge at the SEC’s website at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF AIMA ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTIONS THAT AIMA WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AIMA, DOCTER AND THE PROPOSED TRANSACTIONS.
<div class="lb-trans">与此处描述的拟议交易相关，购买方于 2025 年 3 月 6 日向 SEC 提交了最终招股说明书。代理声明和代理卡已邮寄给截至 2025 年 2 月 25 日的 AIMA 股东。AIMA 的股东还可以免费从 AIMA 获取最终招股说明书。最终招股说明书也可以在 SEC 网站 www.sec.gov 上免费获取。AIMA 的投资者和证券持有人被敦促阅读这些材料（包括任何修订或补充）以及 AIMA 在拟议交易中提交给 SEC 的任何其他相关文件，因为这些文件将包含有关 AIMA、Docter 和拟议交易的重要信息。
</div>Participants in the Solicitation
<div class="lb-trans">征求参与者
</div>AIMA, Docter, and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of AIMA’s shareholders in connection with the proposed transactions described herein. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of AIMA’s shareholders in connection with the proposed business combination is set forth in the Final Prospectus.
<div class="lb-trans">根据 SEC 规则，AIMA、Docter 及其各自的董事、高级管理人员、其他管理层成员和员工可能被视为参与与此处描述的拟议交易相关的 AIMA 股东的代理征求。有关根据 SEC 规则可能被视为参与 AIMA 股东代理征求的人员的信息已在最终招股说明书中列出。
</div>No Offer or Solicitation
<div class="lb-trans">无报价或征求
</div>This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of any potential transaction and does not constitute an offer to sell or a solicitation of an offer to buy any securities of AIMA, Purchaser or Docter, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.
<div class="lb-trans">本新闻稿不是代理声明或对任何证券的代理、同意或授权的征求，也不构成对 AIMA、购买方或 Docter 的任何证券的出售要约或购买要约的征求，也不应在任何州或司法管辖区内进行任何此类证券的出售，若在该州或司法管辖区内的证券法规定下，未注册或资格审查之前，此类要约、征求或出售将是非法的。证券的任何要约仅应通过符合《证券法》第 10 条要求的招股说明书或其豁免进行。
</div>Aimfinity Investment Corp. I
<div class="lb-trans">Aimfinity Investment Corp. I
</div>I-Fa Chang
<div class="lb-trans">I-Fa Chang
</div>Chief Executive Officer
<div class="lb-trans">首席执行官
</div>221 W 9th St, PMB 235
<div class="lb-trans">221 W 9th St, PMB 235
</div>Wilmington, Delaware 19801
<div class="lb-trans">特拉华州威尔明顿 19801
</div>ceo@aimfinityspac.com
<div class="lb-trans">ceo@aimfinityspac.com
</div><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ETTFNQ00zTXpRd01UUTJJelV3TURFeE56Y3hOZz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxODM1MCM3MzQwMTQ2IzUwMDExNzcxNg=="/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTkxMzI3NzMtNjdmMy00ZDNlLWI4OTgtODM2MTgzYzlhYTU1LTUwMDExNzcxNi0yMDI1LTEyLTMwLWVu/tiny/Aimfinity-Investment-Corp-I.png" alt="" original-src="https://ml.globenewswire.com/media/OTkxMzI3NzMtNjdmMy00ZDNlLWI4OTgtODM2MTgzYzlhYTU1LTUwMDExNzcxNi0yMDI1LTEyLTMwLWVu/tiny/Aimfinity-Investment-Corp-I.png"/>

Aimfinity Investment Corp. I 宣布延长首次业务合并的最后期限 | AIMAU 股票新闻